Company · BIIB
Biogen Inc.
Name as listed on its exchange; filed with the SEC as BIOGEN INC.
Nasdaq's symbol directory lists BIIB on Nasdaq as “Biogen Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 2 occasions ($240K); 2 planned-sale notices; 2 filings by holders of 5% or more; 14 congressional trade disclosures; 4 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Minor Lloyd sold $240K
Every trade (2)
- SELLMinor Lloyd sold $119K
- SELLMinor Lloyd sold $121K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Minor Lloyd $119K
- Minor Lloyd $121K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- STATE STREET CORPORATION 5.1%
- FMR LLC 12.4%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Maria Elvira Salazar (R-FL27): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Kevin Hern (R-OK01): Sale $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
- Maria Elvira Salazar (R-FL27): Sale $15,001 - $50,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- Maria Elvira Salazar (R-FL27): Purchase $1,001 - $15,000
- Maria Elvira Salazar (R-FL27): Purchase $1,001 - $15,000
- Maria Elvira Salazar (R-FL27): Purchase $50,001 - $100,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
3 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Sale: BIOGEN INC $1,001 – $15,000
- Purchase: BIOGEN INC $1,001 – $15,000
- Sale: BIOGEN INC $1,001 – $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Oct 28, 2026
- Results of operations and financial condition Jul 29, 2026
- Results of operations and financial condition Jul 1, 2026
- Submission of matters to a vote of security holders Jun 10, 2026
Lobbying · Senate LDA reports
Lobbying filed
9 quarterly lobbying reports for 2026 naming Biogen Inc. as the client: 9 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- DLA PIPER LLP (US) $60K
- TODD STRATEGY GROUP $50K
- FEDERAL STREET STRATEGIES, LLC $50K
- DLA PIPER LLP (US) $60K
- FEDERAL STREET STRATEGIES, LLC $50K
- TODD STRATEGY GROUP $50K
- DLA PIPER LLP (US) $60K
- FEDERAL STREET STRATEGIES, LLC $50K
- TODD STRATEGY GROUP $50K
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.